{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:55:26Z","timestamp":1792803326912,"version":"4.5.0"},"reference-count":315,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"No Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40265-016-0600-5","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T04:19:48Z","timestamp":1466050788000},"page":"1093-1118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Psychosis in Parkinson\u2019s Disease: Epidemiology, Pathophysiology, and Management"],"prefix":"10.1007","volume":"76","author":[{"given":"Anna","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"key":"600_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","volume":"21","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Aguera-Ortiz L, Weintraub D, et al. Neuropsychiatric symptoms and caregiver\u2019s burden in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21:629\u201334.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.25652","volume":"29","author":"LM Lau de","year":"2014","unstructured":"de Lau LM, Verbaan D, van Rooden SM, Marinus J, van Hilten JJ. Relation of clinical subtypes in Parkinson\u2019s disease with survival. Mov Disord. 2014;29:150\u20131.","journal-title":"Mov Disord."},{"key":"600_CR3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061\u20138.","journal-title":"Mov Disord."},{"key":"600_CR4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American\u00a0Academy\u00a0of\u00a0Neurology. Neurology. 2006;66:996\u20131002.","journal-title":"Neurology."},{"key":"600_CR5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","volume":"23","author":"HH Fernandez","year":"2008","unstructured":"Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster AI, et al. Scales to assess psychosis in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2008;23:484\u2013500.","journal-title":"Mov Disord."},{"key":"600_CR6","first-page":"280","volume":"21","author":"G Friedberg","year":"1998","unstructured":"Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21:280\u20134.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s00415-005-0816-x","volume":"252","author":"D Brandstaedter","year":"2005","unstructured":"Brandstaedter D, Spieker S, Ulm G, Siebert U, Eichhorn TE, Krieg JC, et al. Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson\u2019s disease. J Neurol. 2005;252:1060\u20136.","journal-title":"J Neurol."},{"key":"600_CR8","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","volume":"57","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson\u2019s disease. Neurology. 2001;57:2078\u201382.","journal-title":"Neurology."},{"key":"600_CR9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord. 2005;20:958\u201363.","journal-title":"Mov Disord."},{"key":"600_CR10","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308\u201314.","journal-title":"Neurology."},{"key":"600_CR11","first-page":"S9","volume":"48","author":"B Reisberg","year":"1987","unstructured":"Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer\u2019s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:S9\u201315.","journal-title":"J Clin Psychiatry."},{"key":"600_CR12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/geronj\/39.2.194","volume":"39","author":"SA Beller","year":"1984","unstructured":"Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. J Gerontol. 1984;39:194\u2013200.","journal-title":"J Gerontol."},{"key":"600_CR13","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989;7:59\u201367.","DOI":"10.1192\/S0007125000291514"},{"key":"600_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-440X(94)90059-Q","volume":"35","author":"IH Minas","year":"1994","unstructured":"Minas IH, Klimidis S, Stuart GW, Copolov DL, Singh BS. Positive and negative symptoms in the psychoses: principal components analysis of items from the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms. Compr Psychiatry. 1994;35:135\u201344.","journal-title":"Compr Psychiatry."},{"key":"600_CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2466\/pr0.1966.19.1.180","volume":"19","author":"G Honigfeld","year":"1966","unstructured":"Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep. 1966;19:180\u20132.","journal-title":"Psychol Rep."},{"key":"600_CR16","doi-asserted-by":"crossref","unstructured":"Guy W. Clinical Global Impressions (CGI). In: ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, NIMH;1976. p. 217\u201322.","DOI":"10.1037\/e591322011-001"},{"key":"600_CR17","first-page":"153","volume-title":"Recent developments in Parkinsons disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, UPDRS program members. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinsons disease, vol. 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153\u201363."},{"key":"600_CR18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/mds.26522","volume":"31","author":"P Martinez-Martin","year":"2016","unstructured":"Martinez-Martin P, Leentjens AF, de Pedro-Cuesta J, Chaudhuri KR, Schrag AE, Weintraub D. Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson\u2019s disease. Mov Disord. 2016;31:270\u20139.","journal-title":"Mov Disord."},{"key":"600_CR19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G Fenelon","year":"2000","unstructured":"Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733\u201345.","journal-title":"Brain."},{"key":"600_CR20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;70:734\u20138.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s004150200032","volume":"249","author":"A Schrag","year":"2002","unstructured":"Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson\u2019s disease? J Neurol. 2002;249:419\u201323.","journal-title":"J Neurol."},{"key":"600_CR22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","volume":"63","author":"L Marsh","year":"2004","unstructured":"Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63:293\u2013300.","journal-title":"Neurology."},{"key":"600_CR23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","volume":"20","author":"C Pacchetti","year":"2005","unstructured":"Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease. Mov Disord. 2005;20:1439\u201348.","journal-title":"Mov Disord."},{"key":"600_CR24","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1212\/01.WNL.0000161872.85903.8E","volume":"64","author":"D Paleacu","year":"2005","unstructured":"Paleacu D, Schechtman E, Inzelberg R. Association between family history of dementia and hallucinations in Parkinson disease. Neurology. 2005;64:1712\u20135.","journal-title":"Neurology."},{"key":"600_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2377-8-21","volume":"8","author":"S Papapetropoulos","year":"2008","unstructured":"Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson\u2019s disease. BMC Neurol. 2008;8:21.","journal-title":"BMC Neurol."},{"key":"600_CR26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/jnnp.2007.124677","volume":"79","author":"DR Williams","year":"2008","unstructured":"Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2008;79:652\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","volume":"25","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:763\u20136.","journal-title":"Mov Disord."},{"key":"600_CR28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/JGP.0b013e31821f1b41","volume":"20","author":"J Mack","year":"2012","unstructured":"Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20:123\u201332.","journal-title":"Am J Geriatr Psychiatry."},{"key":"600_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","volume":"289","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci. 2010;289:12\u20137.","journal-title":"J Neurol Sci."},{"key":"600_CR30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","volume":"63","author":"CG Goetz","year":"2006","unstructured":"Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease. Arch Neurol. 2006;63:713\u20136.","journal-title":"Arch Neurol."},{"key":"600_CR31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, Perez J, Ribosa-Nogue R, Marin J, et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov Disord. 2016;31:45\u201352.","journal-title":"Mov Disord."},{"key":"600_CR32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mds.20263","volume":"20","author":"AD Maindreville de","year":"2005","unstructured":"de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson\u2019s disease: a follow-up study. Mov Disord. 2005;20:212\u20137.","journal-title":"Mov Disord."},{"key":"600_CR33","first-page":"263","volume":"6","author":"RA Wood","year":"2015","unstructured":"Wood RA, Hopkins SA, Moodley KK, Chan D. Fifty percent prevalence of extracampine hallucinations in Parkinson\u2019s disease patients. Front Neurol. 2015;6:263.","journal-title":"Front Neurol."},{"key":"600_CR34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996\u20131001.","journal-title":"Arch Neurol."},{"key":"600_CR35","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/mds.23835","volume":"26","author":"CG Goetz","year":"2011","unstructured":"Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years. Mov Disord. 2011;26:2196\u2013200.","journal-title":"Mov Disord."},{"key":"600_CR36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","volume":"15","author":"CL Dotchin","year":"2009","unstructured":"Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania. Parkinsonism Relat Disord. 2009;15:457\u201360.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/01.WNL.0000103444.45882.D8","volume":"62","author":"V Biousse","year":"2004","unstructured":"Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson\u2019s disease. Neurology. 2004;62:177\u201380.","journal-title":"Neurology."},{"key":"600_CR38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","volume":"80","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2009;80:928\u201330.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"P Riva de la","year":"2014","unstructured":"de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology. 2014;83:1096\u2013103.","journal-title":"Neurology."},{"key":"600_CR40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov Disord. 2015;30:919\u201327.","journal-title":"Mov Disord."},{"key":"600_CR41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","volume":"218","author":"FK Goodwin","year":"1971","unstructured":"Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218:1915\u201320.","journal-title":"JAMA."},{"key":"600_CR42","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484\u201391.","journal-title":"N Engl J Med."},{"key":"600_CR43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/mds.10530","volume":"18","author":"J Herzog","year":"2003","unstructured":"Herzog J, Reiff J, Krack P, Witt K, Schrader B, Muller D, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson\u2019s disease. Mov Disord. 2003;18:1382\u20134.","journal-title":"Mov Disord."},{"key":"600_CR44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284:1931\u20138.","journal-title":"JAMA"},{"key":"600_CR45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-004-0209-9","volume":"111","author":"D Merims","year":"2004","unstructured":"Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson\u2019s disease. J Neural Transm (Vienna). 2004;111:1447\u201353.","journal-title":"J Neural Transm (Vienna)."},{"key":"600_CR46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00415-005-0840-x","volume":"252","author":"S Papapetropoulos","year":"2005","unstructured":"Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson\u2019s disease. J Neurol. 2005;252:1223\u20138.","journal-title":"J Neurol."},{"key":"600_CR47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","volume":"66","author":"G Fenelon","year":"2006","unstructured":"Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66:93\u20138.","journal-title":"Neurology."},{"key":"600_CR48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56:595\u2013601.","journal-title":"Arch Neurol."},{"key":"600_CR49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","volume":"50","author":"CG Goetz","year":"1998","unstructured":"Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, et al. Intravenous levodopa in hallucinating Parkinson\u2019s disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50:515\u20137.","journal-title":"Neurology."},{"key":"600_CR50","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","volume":"82","author":"G Fenelon","year":"2011","unstructured":"Fenelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Levi AC. Feeling of presence in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82:1219\u201324.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","volume":"4","author":"DR Williams","year":"2005","unstructured":"Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson\u2019s disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605\u201310.","journal-title":"Lancet Neurol."},{"key":"600_CR52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2377-9-23","volume":"9","author":"D Ecker","year":"2009","unstructured":"Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson\u2019s disease: a case-control study. BMC Neurol. 2009;9:23.","journal-title":"BMC Neurol."},{"key":"600_CR53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","volume":"15","author":"WL Baker","year":"2009","unstructured":"Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, et al. Dopamine agonists in the treatment of early Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord. 2009;15:287\u201394.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR54","first-page":"CD006564","volume":"2","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;2:CD006564.","journal-title":"Cochrane Database Syst Rev"},{"key":"600_CR55","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/mds.25129","volume":"27","author":"M Poletti","year":"2012","unstructured":"Poletti M, Perugi G, Logi C, Romano A, Del Dotto P, Ceravolo R, et al. Dopamine agonists and delusional jealousy in Parkinson\u2019s disease: a cross-sectional prevalence study. Mov Disord. 2012;27:1679\u201382.","journal-title":"Mov Disord."},{"key":"600_CR56","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.parkreldis.2014.09.019","volume":"20","author":"M Poletti","year":"2014","unstructured":"Poletti M, Lucetti C, Baldacci F, Del Dotto P, Bonuccelli U. Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson\u2019s disease: a case series. Parkinsonism Relat Disord. 2014;20:1290\u20132.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jnnp-2012-304440","volume":"84","author":"RP Munhoz","year":"2013","unstructured":"Munhoz RP, Teive HA, Eleftherohorinou H, Coin LJ, Lees AJ, Silveira-Moriyama L. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84:883\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","volume":"70","author":"J Barnes","year":"2001","unstructured":"Barnes J, David AS. Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70:727\u201333.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.parkreldis.2013.04.001","volume":"19","author":"A Yoritaka","year":"2013","unstructured":"Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, Nakahara T, et al. Motor and non-motor symptoms of 1453 patients with Parkinson\u2019s disease: prevalence and risks. Parkinsonism Relat Disord. 2013;19:725\u201331.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR60","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/mds.23806","volume":"26","author":"SA Factor","year":"2011","unstructured":"Factor SA, Steenland NK, Higgins DS, Molho ES, Kay DM, Montimurro J, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson\u2019s disease. Mov Disord. 2011;26:2190\u20135.","journal-title":"Mov Disord."},{"key":"600_CR61","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/jnnp.65.4.610","volume":"65","author":"SS Shergill","year":"1998","unstructured":"Shergill SS, Walker Z, Le Katona C. A preliminary investigation of laterality in Parkinson\u2019s disease and susceptibility to psychosis. J Neurol Neurosurg Psychiatry. 1998;65:610\u20131.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR62","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.51.3.811","volume":"51","author":"CG Goetz","year":"1998","unstructured":"Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998;51:811\u20134.","journal-title":"Neurology."},{"key":"600_CR63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","volume":"64","author":"CG Goetz","year":"2005","unstructured":"Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005;64:81\u20136.","journal-title":"Neurology."},{"key":"600_CR64","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837\u201344.","journal-title":"Mov Disord."},{"key":"600_CR65","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson\u2019s disease. A prospective study. Mov Disord. 2007;22:938\u201345.","journal-title":"Mov Disord."},{"key":"600_CR66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","volume":"27","author":"AH Lee","year":"2012","unstructured":"Lee AH, Weintraub D. Psychosis in Parkinson\u2019s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27:858\u201363.","journal-title":"Mov Disord."},{"key":"600_CR67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/mds.22512","volume":"24","author":"SM Rooden van","year":"2009","unstructured":"van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Motor patterns in Parkinson\u2019s disease: a data-driven approach. Mov Disord. 2009;24:1042\u20137.","journal-title":"Mov Disord."},{"key":"600_CR68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.parkreldis.2014.12.020","volume":"21","author":"EB Forsaa","year":"2015","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. A 12-year population-based study of freezing of gait in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21:254\u20138.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mds.25650","volume":"29","author":"CR Baumann","year":"2014","unstructured":"Baumann CR, Held U, Valko PO, Wienecke M, Waldvogel D. Body side and predominant motor features at the onset of Parkinson\u2019s disease are linked to motor and nonmotor progression. Mov Disord. 2014;29:207\u201313.","journal-title":"Mov Disord."},{"key":"600_CR70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2012.09.007","volume":"323","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Vaid HM, Edun A, Dogu O, Rana MA. Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson\u2019s disease. J Neurol Sci. 2012;323:158\u201361.","journal-title":"J Neurol Sci."},{"key":"600_CR71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mds.22896","volume":"25","author":"E Cubo","year":"2010","unstructured":"Cubo E, Martin PM, Martin-Gonzalez JA, Rodriguez-Blazquez C, Kulisevsky J, Members EG. Motor laterality asymmetry and nonmotor symptoms in Parkinson\u2019s disease. Mov Disord. 2010;25:70\u20135.","journal-title":"Mov Disord."},{"key":"600_CR72","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/WNN.0b013e318185e698","volume":"21","author":"K Stavitsky","year":"2008","unstructured":"Stavitsky K, McNamara P, Durso R, Harris E, Auerbach S, Cronin-Golomb A. Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neurol. 2008;21:143\u20139.","journal-title":"Cogn Behav Neurol."},{"key":"600_CR73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2377-13-145","volume":"13","author":"H Sawada","year":"2013","unstructured":"Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, et al. Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol. 2013;13:145.","journal-title":"BMC Neurol."},{"key":"600_CR74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.20701","volume":"21","author":"CG Goetz","year":"2006","unstructured":"Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson\u2019s disease patients. Mov Disord. 2006;21:267\u201370.","journal-title":"Mov Disord."},{"key":"600_CR75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00415-006-0388-4","volume":"254","author":"G Kiziltan","year":"2007","unstructured":"Kiziltan G, Ozekmekci S, Ertan S, Ertan T, Erginoz E. Relationship between age and subtypes of psychotic symptoms in Parkinson\u2019s disease. J Neurol. 2007;254:448\u201352.","journal-title":"J Neurol."},{"key":"600_CR76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00415-012-6600-9","volume":"260","author":"V Spica","year":"2013","unstructured":"Spica V, Pekmezovic T, Svetel M, Kostic VS. Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson\u2019s disease. J Neurol. 2013;260:131\u20137.","journal-title":"J Neurol."},{"key":"600_CR77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/awg142","volume":"126","author":"NL Khan","year":"2003","unstructured":"Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, et al. Parkin disease: a phenotypic study of a large case series. Brain. 2003;126:1279\u201392.","journal-title":"Brain."},{"key":"600_CR78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000327098.86861.d4","volume":"72","author":"E Lohmann","year":"2009","unstructured":"Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ, et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology. 2009;72:110\u20136.","journal-title":"Neurology."},{"key":"600_CR79","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/jnnp.2006.105676","volume":"78","author":"S Steinlechner","year":"2007","unstructured":"Steinlechner S, Stahlberg J, Volkel B, Djarmati A, Hagenah J, Hiller A, et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry. 2007;78:532\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.21380","volume":"63","author":"OA Ross","year":"2008","unstructured":"Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743\u201350.","journal-title":"Ann Neurol."},{"key":"600_CR81","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20753","volume":"59","author":"K Nishioka","year":"2006","unstructured":"Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson\u2019s disease. Ann Neurol. 2006;59:298\u2013309.","journal-title":"Ann Neurol."},{"key":"600_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.01.028","author":"S Takamura","year":"2016","unstructured":"Takamura S, Ikeda A, Nishioka K, Furuya H, Tashiro M, Matsushima T, et al. Schizophrenia as a prodromal symptom in a patient harboring SNCA duplication. Parkinsonism Relat Disord. 2016. doi: 10.1016\/j.parkreldis.2016.01.028 .","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR83","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.parkreldis.2010.09.003","volume":"16","author":"S Belarbi","year":"2010","unstructured":"Belarbi S, Hecham N, Lesage S, Kediha MI, Smail N, Benhassine T, et al. LRRK2 G2019S mutation in Parkinson\u2019s disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat Disord. 2010;16:676\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR84","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.parkreldis.2006.04.001","volume":"12","author":"S Goldwurm","year":"2006","unstructured":"Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, et al. LRRK2 G2019S mutation and Parkinson\u2019s disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord. 2006;12:410\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR85","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.parkreldis.2015.02.019","volume":"21","author":"JH Somme","year":"2015","unstructured":"Somme JH, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, et al. Cognitive and behavioral symptoms in Parkinson\u2019s disease patients with the G2019S and R1441G mutations of the LRRK2 gene. Parkinsonism Relat Disord. 2015;21:494\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR86","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.neurobiolaging.2015.08.027","volume":"36","author":"T Oeda","year":"2015","unstructured":"Oeda T, Umemura A, Mori Y, Tomita S, Kohsaka M, Park K, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson\u2019s disease. Neurobiol Aging. 2015;36:3306\u201313.","journal-title":"Neurobiol Aging."},{"key":"600_CR87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-0404.2007.00860.x","volume":"116","author":"M Kitayama","year":"2007","unstructured":"Kitayama M, Wada-Isoe K, Nakaso K, Irizawa Y, Nakashima K. Clinical evaluation of Parkinson\u2019s disease dementia: association with aging and visual hallucination. Acta Neurol Scand. 2007;116:190\u20135.","journal-title":"Acta Neurol Scand."},{"key":"600_CR88","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mds.25873","volume":"29","author":"D Aarsland","year":"2014","unstructured":"Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. Mov Disord. 2014;29:651\u201362.","journal-title":"Mov Disord."},{"key":"600_CR89","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/mds.25389","volume":"28","author":"K Zhu","year":"2013","unstructured":"Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson\u2019s disease: results from a large prospective cohort study. Mov Disord. 2013;28:755\u201362.","journal-title":"Mov Disord."},{"key":"600_CR90","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528\u201336.","journal-title":"Int J Geriatr Psychiatry."},{"key":"600_CR91","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","volume":"69","author":"KM Biglan","year":"2007","unstructured":"Biglan KM, Holloway RG Jr, McDermott MP, Richard IH, Parkinson Study Group C-PDI. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69:187\u201395.","journal-title":"Neurology."},{"key":"600_CR92","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/mds.23891","volume":"26","author":"NK Archibald","year":"2011","unstructured":"Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Mov Disord. 2011;26:2387\u201395.","journal-title":"Mov Disord."},{"key":"600_CR93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289:18\u201322.","journal-title":"J Neurol Sci."},{"key":"600_CR94","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/archneur.61.12.1906","volume":"61","author":"D Aarsland","year":"2004","unstructured":"Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61:1906\u201311.","journal-title":"Arch Neurol."},{"key":"600_CR95","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","volume":"81","author":"N Ibarretxe-Bilbao","year":"2010","unstructured":"Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Bargallo N, et al. Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010;81:650\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR96","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.parkreldis.2013.04.026","volume":"19","author":"DH Hepp","year":"2013","unstructured":"Hepp DH, da Hora CC, Koene T, Uitdehaag BM, van den Heuvel OA, Klein M, et al. Cognitive correlates of visual hallucinations in non-demented Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2013;19:795\u20139.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR97","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/mds.22270","volume":"23","author":"AM Meppelink","year":"2008","unstructured":"Meppelink AM, Koerts J, Borg M, Leenders KL, van Laar T. Visual object recognition and attention in Parkinson\u2019s disease patients with visual hallucinations. Mov Disord. 2008;23:1906\u201312.","journal-title":"Mov Disord."},{"key":"600_CR98","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jnnp.2007.116202","volume":"79","author":"J Barnes","year":"2008","unstructured":"Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson\u2019s disease with visual hallucinations. J Neurol Neurosurg Psychiatry. 2008;79:190\u20132.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR99","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/mds.23411","volume":"25","author":"G Llebaria","year":"2010","unstructured":"Llebaria G, Pagonabarraga J, Martinez-Corral M, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson\u2019s disease. Mov Disord. 2010;25:2785\u201391.","journal-title":"Mov Disord."},{"key":"600_CR100","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mds.23525","volume":"26","author":"K Bronnick","year":"2011","unstructured":"Bronnick K, Emre M, Tekin S, Haugen SB, Aarsland D. Cognitive correlates of visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord. 2011;26:824\u20139.","journal-title":"Mov Disord."},{"key":"600_CR101","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/mds.20965","volume":"21","author":"B Ramirez-Ruiz","year":"2006","unstructured":"Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Neuropsychological deficits in Parkinson\u2019s disease patients with visual hallucinations. Mov Disord. 2006;21:1483\u20137.","journal-title":"Mov Disord."},{"key":"600_CR102","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/jnnp-2012-303391","volume":"83","author":"S Shin","year":"2012","unstructured":"Shin S, Lee JE, Hong JY, Sunwoo MK, Sohn YH, Lee PH. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2012;83:1155\u201361.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR103","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jocn.2006.05.006","volume":"14","author":"F Ozer","year":"2007","unstructured":"Ozer F, Meral H, Hanoglu L, Ozturk O, Aydemir T, Cetin S, et al. Cognitive impairment patterns in Parkinson\u2019s disease with visual hallucinations. J Clin Neurosci. 2007;14:742\u20136.","journal-title":"J Clin Neurosci."},{"key":"600_CR104","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/gps.1339","volume":"20","author":"D Grossi","year":"2005","unstructured":"Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry. 2005;20:668\u201373.","journal-title":"Int J Geriatr Psychiatry."},{"key":"600_CR105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1017\/S0140525X05000130","volume":"28","author":"D Collerton","year":"2005","unstructured":"Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci. 2005;28:737\u201357.","journal-title":"Behav Brain Sci."},{"key":"600_CR106","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.20308","volume":"20","author":"NJ Diederich","year":"2005","unstructured":"Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson\u2019s disease as disturbed external\/internal perceptions: focused review and a new integrative model. Mov Disord. 2005;20:130\u201340.","journal-title":"Mov Disord."},{"key":"600_CR107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2015.06.037","volume":"356","author":"H Alzahrani","year":"2015","unstructured":"Alzahrani H, Venneri A. Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson\u2019s disease: a systematic review. J Neurol Sci. 2015;356:32\u201344.","journal-title":"J Neurol Sci."},{"key":"600_CR108","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/brain\/awt360","volume":"137","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson\u2019s disease with hallucinations. Brain. 2014;137:849\u201359.","journal-title":"Brain."},{"key":"600_CR109","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/hbm.23080","volume":"37","author":"C Gasca-Salas","year":"2016","unstructured":"Gasca-Salas C, Clavero P, Garcia-Garcia D, Obeso JA, Rodriguez-Oroz MC. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson\u2019s disease patients with mild cognitive impairment. Hum Brain Mapp. 2016;37:968\u201377.","journal-title":"Hum Brain Mapp."},{"key":"600_CR110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jns.2014.10.033","volume":"347","author":"SA Factor","year":"2014","unstructured":"Factor SA, Scullin MK, Sollinger AB, Land JO, Wood-Siverio C, Zanders L, et al. Cognitive correlates of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Sci. 2014;347:316\u201321.","journal-title":"J Neurol Sci."},{"key":"600_CR111","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.parkreldis.2010.06.010","volume":"16","author":"N Stefanis","year":"2010","unstructured":"Stefanis N, Bozi M, Christodoulou C, Douzenis A, Gasparinatos G, Stamboulis E, et al. Isolated delusional syndrome in Parkinson\u2019s Disease. Parkinsonism Relat Disord. 2010;16:550\u20132.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR112","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"EJ Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord. 1999;14:117\u201321.","journal-title":"Mov Disord."},{"key":"600_CR113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1179\/1743132814Y.0000000418","volume":"37","author":"RL Gama","year":"2015","unstructured":"Gama RL, de Bruin VM, de Bruin PF, Tavora DG, Lopes EM, Jorge IF, et al. Risk factors for visual hallucinations in patients with Parkinson\u2019s disease. Neurol Res. 2015;37:112\u20136.","journal-title":"Neurol Res."},{"key":"600_CR114","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/mds.10439","volume":"18","author":"T Nomura","year":"2003","unstructured":"Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson\u2019s disease. Mov Disord. 2003;18:812\u20137.","journal-title":"Mov Disord."},{"key":"600_CR115","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1212\/01.WNL.0000038351.32678.4A","volume":"59","author":"R Manni","year":"2002","unstructured":"Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology. 2002;59:1979\u201381.","journal-title":"Neurology."},{"key":"600_CR116","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.410340514","volume":"34","author":"CL Comella","year":"1993","unstructured":"Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson\u2019s disease patients with treatment-induced hallucinations. Ann Neurol. 1993;34:710\u20134.","journal-title":"Ann Neurol."},{"key":"600_CR117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/jnnp.2007.116830","volume":"79","author":"MD Gjerstad","year":"2008","unstructured":"Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson\u2019s disease over time. J Neurol Neurosurg Psychiatry. 2008;79:387\u201391.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","volume":"55","author":"I Arnulf","year":"2000","unstructured":"Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson\u2019s disease: a medical hypothesis. Neurology. 2000;55:281\u20138.","journal-title":"Neurology."},{"key":"600_CR119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-0404.2006.00644.x","volume":"114","author":"G Benbir","year":"2006","unstructured":"Benbir G, Ozekmekci S, Cinar M, Beskardes F, Apaydin H, Erginoz E. Features associated with the development of hallucinations in Parkinson\u2019s disease. Acta Neurol Scand. 2006;114:239\u201343.","journal-title":"Acta Neurol Scand."},{"key":"600_CR120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/mds.22126","volume":"23","author":"E Sinforiani","year":"2008","unstructured":"Sinforiani E, Pacchetti C, Zangaglia R, Pasotti C, Manni R, Nappi G. REM behavior disorder, hallucinations and cognitive impairment in Parkinson\u2019s disease: a two-year follow up. Mov Disord. 2008;23:1441\u20135.","journal-title":"Mov Disord."},{"key":"600_CR121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.11.018","volume":"22","author":"A Lenka","year":"2016","unstructured":"Lenka A, Hegde S, Jhunjhunwala KR, Pal PK. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson\u2019s disease: a review. Parkinsonism Relat Disord. 2016;22:1\u20138.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0891988705284739","volume":"19","author":"H Matsui","year":"2006","unstructured":"Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2006;19:36\u201340.","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"600_CR123","first-page":"289","volume":"21","author":"NJ Diederich","year":"1998","unstructured":"Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson\u2019s disease. Clin Neuropharmacol. 1998;21:289\u201395.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.25543","volume":"29","author":"JY Lee","year":"2014","unstructured":"Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson\u2019s Disease. Mov Disord. 2014;29:61\u20137.","journal-title":"Mov Disord."},{"key":"600_CR125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/mds.25747","volume":"29","author":"B Jimenez","year":"2014","unstructured":"Jimenez B, Ascaso FJ, Cristobal JA, Lopez del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord. 2014;29:68\u201374.","journal-title":"Mov Disord."},{"key":"600_CR126","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ana.24182","volume":"75","author":"I Bodis-Wollner","year":"2014","unstructured":"Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. alpha-synuclein in the inner retina in parkinson disease. Ann Neurol. 2014;75:964\u20136.","journal-title":"Ann Neurol."},{"key":"600_CR127","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/brain\/awu094","volume":"137","author":"NJ Diederich","year":"2014","unstructured":"Diederich NJ, Stebbins G, Schiltz C, Goetz CG. Are patients with Parkinson\u2019s disease blind to blindsight? Brain. 2014;137:1838\u201349.","journal-title":"Brain."},{"key":"600_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26533","author":"JY Lee","year":"2016","unstructured":"Lee JY, Yoon EJ, Lee WW, Kim YK, Lee JY, Jeon B. Lateral geniculate atrophy in Parkinson\u2019s with visual hallucination: a trans-synaptic degeneration? Mov Disord. 2016. doi: 10.1002\/mds.26533 .","journal-title":"Mov Disord."},{"key":"600_CR129","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","volume":"53","author":"JR Sanchez-Ramos","year":"1996","unstructured":"Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265\u20138.","journal-title":"Arch Neurol."},{"key":"600_CR130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","volume":"64","author":"R Inzelberg","year":"1998","unstructured":"Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1998;64:533\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","volume":"107","author":"N Giladi","year":"2000","unstructured":"Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson\u2019s disease. J Neural Transm. 2000;107:59\u201371.","journal-title":"J Neural Transm."},{"key":"600_CR132","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.parkreldis.2006.03.006","volume":"12","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2006;12:427\u201331.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR133","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jnnp-2011-300043","volume":"83","author":"L Morgante","year":"2012","unstructured":"Morgante L, Colosimo C, Antonini A, Marconi R, Meco G, Pederzoli M, et al. Psychosis associated to Parkinson\u2019s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012;83:76\u201382.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR134","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10286-015-0270-5","volume":"25","author":"E Stuebner","year":"2015","unstructured":"Stuebner E, Vichayanrat E, Low DA, Mathias CJ, Isenmann S, Haensch CA. Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. Clin Auton Res. 2015;25:109\u201316.","journal-title":"Clin Auton Res."},{"key":"600_CR135","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/mds.23792","volume":"26","author":"JF Morley","year":"2011","unstructured":"Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE. Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson\u2019s disease. Mov Disord. 2011;26:2051\u20137.","journal-title":"Mov Disord."},{"key":"600_CR136","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/mds.23782","volume":"26","author":"MF Damholdt","year":"2011","unstructured":"Damholdt MF, Borghammer P, Larsen L, Ostergaard K. Odor identification deficits identify Parkinson\u2019s disease patients with poor cognitive performance. Mov Disord. 2011;26:2045\u201350.","journal-title":"Mov Disord."},{"key":"600_CR137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","volume":"10","author":"AJ Makoff","year":"2000","unstructured":"Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson\u2019s disease. Pharmacogenetics. 2000;10:43\u20138.","journal-title":"Pharmacogenetics."},{"key":"600_CR138","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","volume":"58","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58:209\u201313.","journal-title":"Arch Neurol."},{"key":"600_CR139","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008571-200306000-00008","volume":"13","author":"J Wang","year":"2003","unstructured":"Wang J, Si YM, Liu ZL, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson\u2019s disease. Pharmacogenetics. 2003;13:365\u20139.","journal-title":"Pharmacogenetics."},{"key":"600_CR140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neulet.2007.06.028","volume":"422","author":"L Kiferle","year":"2007","unstructured":"Kiferle L, Ceravolo R, Petrozzi L, Rossi C, Frosini D, Rocchi A, et al. Visual hallucinations in Parkinson\u2019s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422:228\u201331.","journal-title":"Neurosci Lett."},{"key":"600_CR141","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/mds.10409","volume":"18","author":"M Onofrj","year":"2003","unstructured":"Onofrj M, Luciano AL, Iacono D, Thomas A, Stocchi F, Papola F, et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson\u2019s disease. Mov Disord. 2003;18:337\u201340.","journal-title":"Mov Disord."},{"key":"600_CR142","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.20481","volume":"20","author":"R Camicioli","year":"2005","unstructured":"Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson\u2019s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20:989\u201394.","journal-title":"Mov Disord."},{"key":"600_CR143","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.parkreldis.2014.02.001","volume":"20","author":"SE Monsell","year":"2014","unstructured":"Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson\u2019s disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord. 2014;20:503\u20137.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR144","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","volume":"355","author":"J Wang","year":"2004","unstructured":"Wang J, Zhao C, Chen B, Liu ZL. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson\u2019s disease. Neurosci Lett. 2004;355:193\u20136.","journal-title":"Neurosci Lett."},{"key":"600_CR145","first-page":"1280","volume":"61","author":"JG Goldman","year":"2004","unstructured":"Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004;61:1280\u20134.","journal-title":"Arch Neurol."},{"key":"600_CR146","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pnpbp.2011.02.002","volume":"35","author":"P Solla","year":"2011","unstructured":"Solla P, Cannas A, Floris GL, Orofino G, Costantino E, Boi A, et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson\u2019s disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1009\u201313.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"600_CR147","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp-2014-307822","volume":"86","author":"M Lubomski","year":"2015","unstructured":"Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson\u2019s disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2015;86:324\u201330.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR148","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2010.11.009","volume":"17","author":"MJ Aminoff","year":"2011","unstructured":"Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, et al. Management of the hospitalized patient with Parkinson\u2019s disease: current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011;17:139\u201345.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR149","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1474-4422(15)00101-5","volume":"14","author":"TG Fong","year":"2015","unstructured":"Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. Lancet Neurol. 2015;14:823\u201332.","journal-title":"Lancet Neurol."},{"key":"600_CR150","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00415-015-7760-1","volume":"262","author":"ER Vardy","year":"2015","unstructured":"Vardy ER, Teodorczuk A, Yarnall AJ. Review of delirium in patients with Parkinson\u2019s disease. J Neurol. 2015;262:2401\u201310.","journal-title":"J Neurol."},{"key":"600_CR151","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1532-5415.2008.01851.x","volume":"56","author":"BC Munster van","year":"2008","unstructured":"van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE. Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc. 2008;56:1704\u20139.","journal-title":"J Am Geriatr Soc."},{"key":"600_CR152","first-page":"964","volume":"17","author":"L Kouti","year":"2013","unstructured":"Kouti L, Noroozian M, Akhondzadeh S, Abdollahi M, Javadi MR, Faramarzi MA, et al. Nitric oxide and peroxynitrite serum levels in Parkinson\u2019s disease: correlation of oxidative stress and the severity of the disease. Eur Rev Med Pharmacol Sci. 2013;17:964\u201370.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"600_CR153","doi-asserted-by":"crossref","first-page":"e85886","DOI":"10.1371\/journal.pone.0085886","volume":"9","author":"H Sawada","year":"2014","unstructured":"Sawada H, Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M, et al. Subclinical elevation of plasma C-reactive protein and illusions\/hallucinations in subjects with Parkinson\u2019s disease: case\u2013control study. PLoS One. 2014;9:e85886.","journal-title":"PLoS One."},{"key":"600_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2012.07.012","volume":"28","author":"C Cunningham","year":"2013","unstructured":"Cunningham C, Maclullich AM. At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response. Brain Behav Immun. 2013;28:1\u201313.","journal-title":"Brain Behav Immun."},{"key":"600_CR155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00019442-199802000-00005","volume":"6","author":"JM Flacker","year":"1998","unstructured":"Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998;6:31\u201341.","journal-title":"Am J Geriatr Psychiatry."},{"key":"600_CR156","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(13)60688-1","volume":"383","author":"SK Inouye","year":"2014","unstructured":"Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911\u201322.","journal-title":"Lancet."},{"key":"600_CR157","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","volume":"21","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, et al. Pharmacological\u00a0characterization\u00a0of\u00a0psychosis-like\u00a0behavior\u00a0in the\u00a0MPTP-lesioned\u00a0nonhuman\u00a0primate\u00a0model of\u00a0Parkinson\u2019s\u00a0disease. Mov Disord. 2006;21:1879\u201391.","journal-title":"Mov Disord."},{"key":"600_CR158","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391\u2013403.","journal-title":"Brain."},{"key":"600_CR159","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0166-2236(92)90344-8","volume":"15","author":"MA Goodale","year":"1992","unstructured":"Goodale MA, Milner AD. Separate visual pathways for perception and action. Trends Neurosci. 1992;15:20\u20135.","journal-title":"Trends Neurosci."},{"key":"600_CR160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1097-0193(1999)7:1<29::AID-HBM3>3.0.CO;2-R","volume":"7","author":"E Halgren","year":"1999","unstructured":"Halgren E, Dale AM, Sereno MI, Tootell RB, Marinkovic K, Rosen BR. Location of human face-selective cortex with respect to retinotopic areas. Hum Brain Mapp. 1999;7:29\u201337.","journal-title":"Hum Brain Mapp."},{"key":"600_CR161","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0896-6273(04)00070-4","volume":"41","author":"MS Beauchamp","year":"2004","unstructured":"Beauchamp MS, Lee KE, Argall BD, Martin A. Integration of auditory and visual information about objects in superior temporal sulcus. Neuron. 2004;41:809\u201323.","journal-title":"Neuron."},{"key":"600_CR162","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nn1333","volume":"7","author":"MS Beauchamp","year":"2004","unstructured":"Beauchamp MS, Argall BD, Bodurka J, Duyn JH, Martin A. Unraveling multisensory integration: patchy organization within human STS multisensory cortex. Nat Neurosci. 2004;7:1190\u20132.","journal-title":"Nat Neurosci."},{"key":"600_CR163","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.10.005","volume":"12","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson\u2019s disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12:253\u20136.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR164","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.parkreldis.2008.05.007","volume":"15","author":"ME Kalaitzakis","year":"2009","unstructured":"Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RK, Gentleman SM. Dementia and visual hallucinations associated with limbic pathology in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15:196\u2013204.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR165","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/brain\/awf251","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson\u2019s disease. Brain. 2002;125:2431\u201345.","journal-title":"Brain."},{"key":"600_CR166","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.parkreldis.2014.06.018","volume":"20","author":"SA Jacobson","year":"2014","unstructured":"Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord. 2014;20:1009\u201314.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR167","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/neup.12208","volume":"35","author":"T Homma","year":"2015","unstructured":"Homma T, Mochizuki Y, Takahashi K, Komori T. Medial temporal regional argyrophilic grain as a possible important factor affecting dementia in Parkinson\u2019s disease. Neuropathology. 2015;35:441\u201351.","journal-title":"Neuropathology."},{"key":"600_CR168","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1007\/s00415-013-7101-1","volume":"260","author":"O Grau-Rivera","year":"2013","unstructured":"Grau-Rivera O, Gelpi E, Rey MJ, Valldeoriola F, Tolosa E, Compta Y, et al. Prominent psychiatric symptoms in patients with Parkinson\u2019s disease and concomitant argyrophilic grain disease. J Neurol. 2013;260:3002\u20139.","journal-title":"J Neurol."},{"key":"600_CR169","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-510X(00)00359-2","volume":"178","author":"H Seno","year":"2000","unstructured":"Seno H, Kobayashi S, Inagaki T, Yamamori C, Miyaoka T, Horiguchi J, et al. Parkinson\u2019s disease associated with argyrophilic grains clinically resembling progressive supranuclear palsy: an autopsy case. J Neurol Sci. 2000;178:70\u20134.","journal-title":"J Neurol Sci."},{"key":"600_CR170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12031-015-0576-8","volume":"57","author":"MJ Hurley","year":"2015","unstructured":"Hurley MJ, Durrenberger PF, Gentleman SM, Walls AF, Dexter DT. Altered expression of brain proteinase-activated receptor-2, trypsin-2 and serpin proteinase inhibitors in Parkinson\u2019s disease. J Mol Neurosci. 2015;57:48\u201362.","journal-title":"J Mol Neurosci."},{"key":"600_CR171","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1468-1331.2007.01768.x","volume":"14","author":"B Ram\u00edrez-Ruiz","year":"2007","unstructured":"Ram\u00edrez-Ruiz B, Mart\u00ed MJ, Tolosa E, Gim\u00e9nez M, Bargall\u00f3 N, Valldeoriola F, et al. Cerebral atrophy in Parkinson\u2019s disease patients with visual hallucinations. Eur J Neurol. 2007;14:750\u20136.","journal-title":"Eur J Neurol."},{"key":"600_CR172","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00415-008-0885-8","volume":"255","author":"N Ibarretxe-Bilbao","year":"2008","unstructured":"Ibarretxe-Bilbao N, Ram\u00edrez-Ruiz B, Tolosa E, Mart\u00ed MJ, Valldeoriola F, Bargall\u00f3 N, et al. Hippocampal head atrophy predominance in Parkinson\u2019s disease with hallucinations and with dementia. J Neurol. 2008;255:1324\u201331.","journal-title":"J Neurol."},{"key":"600_CR173","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","volume":"81","author":"N Ibarretxe-Bilbao","year":"2010","unstructured":"Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Bargallo N, et al. Differential progression of brain atrophy in Parkinson\u2019s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010;81:650\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR174","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mds.23375","volume":"26","author":"AM Meppelink","year":"2011","unstructured":"Meppelink AM, de Jong BM, Teune LK, van Laar T. Regional cortical grey matter loss in Parkinson\u2019s disease without dementia is independent from visual hallucinations. Mov Disord. 2011;26:142\u20137.","journal-title":"Mov Disord."},{"key":"600_CR175","doi-asserted-by":"crossref","unstructured":"Janzen J, van\u2019t Ent D, Lemstra AW, Berendse HW, Barkhof F, Foncke EM. The pedunculopontine nucleus is related to visual hallucinations in Parkinson\u2019s disease: preliminary results of a voxel-based morphometry study. J Neurol. 2012;259:147\u201354.","DOI":"10.1007\/s00415-011-6149-z"},{"key":"600_CR176","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/jnnp-2012-303391","volume":"83","author":"S Shin","year":"2012","unstructured":"Shin S, Lee JE, Hong JY, Sunwoo M, Sohn YH, Lee PH. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2012;83:1155\u201361.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR177","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/mds.25641","volume":"28","author":"H Watanabe","year":"2013","unstructured":"Watanabe H, Senda J, Kato S, Ito M, Atsuta N, Hara K, et al. Cortical and subcortical brain atrophy in Parkinson\u2019s disease with visual hallucination. Mov Disord. 2013;28:1732\u20136.","journal-title":"Mov Disord."},{"key":"600_CR178","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.parkreldis.2013.11.017","volume":"20","author":"J Pagonabarraga","year":"2014","unstructured":"Pagonabarraga J, Soriano-Mas C, Llebaria G, L\u00f3pez-Sol\u00e0 M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:290\u20136.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR179","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bandc.2014.03.011","volume":"87","author":"RL Gama","year":"2014","unstructured":"Gama RL, Bruin VM, T\u00e1vora DG, Duran FL, Bittencourt L, Tufik S. Structural brain abnormalities in patients with Parkinson\u2019s disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn. 2014;87:97\u2013103.","journal-title":"Brain Cogn."},{"key":"600_CR180","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/brain\/awt360","volume":"137","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, Detoledo-Morrell L, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson\u2019s disease with hallucinations. Brain. 2014;137:849\u201359.","journal-title":"Brain."},{"key":"600_CR181","first-page":"378032","volume":"2015","author":"V Fioravanti","year":"2015","unstructured":"Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P, et al. MRI correlates of Parkinson\u2019s disease progression: a voxel based morphometry study. Parkinsons Dis. 2015;2015:378032.","journal-title":"Parkinsons Dis."},{"key":"600_CR182","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mds.20129","volume":"19","author":"A Nagano-Saito","year":"2004","unstructured":"Nagano-Saito A, Washimi Y, Arahata Y, Iwai K, Kawatsu S, Ito K, et al. Visual hallucination in Parkinson\u2019s disease with FDG PET. Mov Disord. 2004;19:801\u20136.","journal-title":"Mov Disord."},{"key":"600_CR183","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/archneur.64.7.984","volume":"64","author":"H Boecker","year":"2007","unstructured":"Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64:984\u20138.","journal-title":"Arch Neurol."},{"key":"600_CR184","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0317167100014888","volume":"40","author":"HK Park","year":"2013","unstructured":"Park HK, Kim JS, Im KC, Kim MJ, Lee J-H, Lee MC, et al. Visual hallucinations and cognitive impairment in Parkinson\u2019s disease. Can J Neurol Sci. 2013;40:657\u201362.","journal-title":"Can J Neurol Sci."},{"key":"600_CR185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s004150050364","volume":"246","author":"K Okada","year":"1999","unstructured":"Okada K, Suyama N, Kobayashi S, Oguro H, Yamaguchi S. Medication-induced hallucination and cerebral blood flow in Parkinson\u2019s disease. J Neurol. 1999;246:365\u20138.","journal-title":"J Neurol."},{"key":"600_CR186","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/01.wnl.0000187116.13370.e0","volume":"65","author":"N Oishi","year":"2005","unstructured":"Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708\u201315.","journal-title":"Neurology."},{"key":"600_CR187","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/mds.21140","volume":"21","author":"H Matsui","year":"2006","unstructured":"Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006;21:2140\u20134.","journal-title":"Mov Disord."},{"key":"600_CR188","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.parkreldis.2014.04.006","volume":"20","author":"L Kiferle","year":"2014","unstructured":"Kiferle L, Ceravolo R, Giuntini M, Linsalata G, Puccini G, Volterrani D, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a 123I-FP-CIT SPECT study. Parkinsonism Relat Disord. 2014;20:761\u20135.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR189","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"GT Stebbins","year":"2004","unstructured":"Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409\u201316.","journal-title":"Neurology."},{"key":"600_CR190","doi-asserted-by":"crossref","unstructured":"Holroyd S, Wooten GF. Preliminary FMRI evidence of visual system dysfunction in Parkinson\u2019s disease patients with visual hallucinations. J Neuropsychiatry Clin Neurosci. 2006;18:402\u20134.","DOI":"10.1176\/jnp.2006.18.3.402"},{"key":"600_CR191","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/mds.22258","volume":"23","author":"B Ram\u00edrez-Ruiz","year":"2008","unstructured":"Ram\u00edrez-Ruiz B, Mart\u00ed MJ, Tolosa E, Falc\u00f3n C, Bargall\u00f3 N, Valldeoriola F, et al. Brain response to complex visual stimuli in Parkinson\u2019s patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord. 2008;23:2335\u201343.","journal-title":"Mov Disord."},{"key":"600_CR192","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","volume":"132","author":"AM Meppelink","year":"2009","unstructured":"Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson\u2019s disease patients with visual hallucinations. Brain. 2009;132:2980\u201393.","journal-title":"Brain."},{"key":"600_CR193","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1002\/hbm.22577","volume":"35","author":"N Yao","year":"2014","unstructured":"Yao N, Shek-Kwan Chang R, Cheung C, Pang S, Lau KK, Suckling J, et al. The default mode network is disrupted in Parkinson\u2019s disease with visual hallucinations. Hum Brain Mapp. 2014;35:5658\u201366.","journal-title":"Hum Brain Mapp."},{"key":"600_CR194","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2014.11.020","volume":"21","author":"N Yao","year":"2015","unstructured":"Yao N, Pang S, Cheung C, Chang RS, Lau KK, Suckling J, et al. Resting activity in visual and corticostriatal pathways in Parkinson\u2019s disease with hallucinations. Parkinsonism Relat Disord. 2015;21:131\u20137.","journal-title":"Parkinsonism Relat Disord."},{"key":"600_CR195","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/mds.26285","volume":"30","author":"R Franciotti","year":"2015","unstructured":"Franciotti R, Delli Pizzi S, Perfetti B, Tartaro A, Bonanni L, Thomas A, et al. Default mode network links to visual hallucinations: a comparison between Parkinson\u2019s disease and multiple system atrophy. Mov Disord. 2015;30:1237\u201347.","journal-title":"Mov Disord."},{"key":"600_CR196","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00429-014-0907-5","volume":"221","author":"N Yao","year":"2016","unstructured":"Yao N, Cheung C, Pang S, Shek-kwan Chang R, Lau KK, Suckling J, et al. Multimodal MRI of the hippocampus in Parkinson\u2019s disease with visual hallucinations. Brain Struct Funct. 2016;221:287\u2013300.","journal-title":"Brain Struct Funct."},{"key":"600_CR197","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0031-6997(25)07428-9","volume":"11","author":"A Carlsson","year":"1959","unstructured":"Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11:490\u20133.","journal-title":"Pharmacol Rev."},{"key":"600_CR198","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/ajp.139.11.1526","volume":"139","author":"CG Goetz","year":"1982","unstructured":"Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982;139:494\u20137.","journal-title":"Am J Psychiatry."},{"key":"600_CR199","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.52.1.10","volume":"52","author":"EC Wolters","year":"1999","unstructured":"Wolters EC. Dopaminomimetic psychosis in Parkinson\u2019s disease patients: diagnosis and treatment. Neurology. 1999;52:S10\u20133.","journal-title":"Neurology."},{"key":"600_CR200","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1176\/ajp.135.6.669","volume":"135","author":"C Moskovitz","year":"1978","unstructured":"Moskovitz C, Moses H 3rd, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry. 1978;135:669\u201375.","journal-title":"Am J Psychiatry."},{"key":"600_CR201","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1176\/ajp.133.2.197","volume":"133","author":"SH Snyder","year":"1976","unstructured":"Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976;133:197\u2013202.","journal-title":"Am J Psychiatry."},{"key":"600_CR202","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","volume":"17","author":"P Seeman","year":"2011","unstructured":"Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther. 2011;17:118\u201332.","journal-title":"CNS Neurosci Ther."},{"key":"600_CR203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/syn.20987","volume":"66","author":"P Seeman","year":"2012","unstructured":"Seeman P. Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse. 2012;66:88\u201393.","journal-title":"Synapse."},{"key":"600_CR204","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366\u201375.","journal-title":"Trends Neurosci."},{"key":"600_CR205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev.ne.16.030193.001503","volume":"16","author":"JA Gingrich","year":"1993","unstructured":"Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 1993;16:299\u2013321.","journal-title":"Annu Rev Neurosci."},{"key":"600_CR206","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0149-7634(99)00063-9","volume":"24","author":"D Vallone","year":"2000","unstructured":"Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24:125\u201332.","journal-title":"Neurosci Biobehav Rev."},{"key":"600_CR207","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","volume":"10","author":"P Seeman","year":"2006","unstructured":"Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515\u201331.","journal-title":"Expert Opin Ther Targets."},{"key":"600_CR208","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","volume":"9","author":"E Bezard","year":"2003","unstructured":"Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med. 2003;9:762\u20137.","journal-title":"Nat Med."},{"key":"600_CR209","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5:25\u201343.","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"600_CR210","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00018-010-0293-y","volume":"67","author":"P Rondou","year":"2010","unstructured":"Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci. 2010;67:1971\u201386.","journal-title":"Cell Mol Life Sci."},{"key":"600_CR211","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2013.05.048","volume":"248","author":"J Sun","year":"2013","unstructured":"Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J. Regulation of dopamine D(3) receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience. 2013;248:112\u201326.","journal-title":"Neuroscience."},{"key":"600_CR212","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14737175.2013.853448","volume":"13","author":"T Veselinovic","year":"2013","unstructured":"Veselinovic T, Paulzen M, Grunder G. Cariprazine, a new, orally active dopamine D2\/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013;13:1141\u201359.","journal-title":"Expert Rev Neurother."},{"key":"600_CR213","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189\u2013225.","journal-title":"Physiol Rev."},{"key":"600_CR214","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0014-2999(00)00562-8","volume":"405","author":"JN Oak","year":"2000","unstructured":"Oak JN, Oldenhof J, Van Tol HH. The dopamine D(4) receptor: one decade of research. Eur J Pharmacol. 2000;405:303\u201327.","journal-title":"Eur J Pharmacol."},{"key":"600_CR215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","volume":"172","author":"JM Beaulieu","year":"2015","unstructured":"Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors\u2014IUPHAR Review 13. Br J Pharmacol. 2015;172:1\u201323.","journal-title":"Br J Pharmacol."},{"key":"600_CR216","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF01663632","volume":"37","author":"W Birkmayer","year":"1975","unstructured":"Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37:175\u201382.","journal-title":"J Neural Transm."},{"key":"600_CR217","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505\u201311.","journal-title":"Life Sci."},{"key":"600_CR218","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","volume":"94","author":"M Titeler","year":"1988","unstructured":"Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl). 1988;94:213\u20136.","journal-title":"Psychopharmacology (Berl)."},{"key":"600_CR219","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR220","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","volume":"19","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19:831\u20133.","journal-title":"Mov Disord."},{"key":"600_CR221","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158:360\u20139.","journal-title":"Am J Psychiatry."},{"key":"600_CR222","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","volume":"47","author":"P Seeman","year":"2002","unstructured":"Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27\u201338.","journal-title":"Can J Psychiatry."},{"key":"600_CR223","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238\u201346.","journal-title":"J Pharmacol Exp Ther."},{"key":"600_CR224","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"B Ballanger","year":"2010","unstructured":"Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67:416\u201321.","journal-title":"Arch Neurol."},{"key":"600_CR225","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","volume":"25","author":"P Huot","year":"2010","unstructured":"Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25:1399\u2013408.","journal-title":"Mov Disord."},{"key":"600_CR226","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","volume":"14","author":"S Fahn","year":"1971","unstructured":"Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson\u2019s disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci. 1971;14:427\u201355.","journal-title":"J Neurol Sci."},{"key":"600_CR227","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease. Brain Res. 1990;510:104\u20137.","journal-title":"Brain Res."},{"key":"600_CR228","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0031-6997(25)07220-5","volume":"18","author":"NA Hillarp","year":"1966","unstructured":"Hillarp NA, Fuxe K, Dahlstrom A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol Rev. 1966;18:727\u201341.","journal-title":"Pharmacol Rev."},{"key":"600_CR229","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819\u201333.","journal-title":"Brain."},{"key":"600_CR230","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1523\/JNEUROSCI.16-11-03727.1996","volume":"16","author":"N Laprade","year":"1996","unstructured":"Laprade N, Radja F, Reader TA, Soghomonian JJ. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J Neurosci. 1996;16:3727\u201336.","journal-title":"J Neurosci."},{"key":"600_CR231","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0006-8993(93)90995-Y","volume":"606","author":"F Radja","year":"1993","unstructured":"Radja F, Descarries L, Dewar KM, Reader TA. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res. 1993;606:273\u201385.","journal-title":"Brain Res."},{"key":"600_CR232","first-page":"23","volume":"37","author":"PA Nausieda","year":"1983","unstructured":"Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol. 1983;37:23\u201332.","journal-title":"Adv Neurol."},{"key":"600_CR233","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","volume":"21","author":"D Burn","year":"2006","unstructured":"Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease. Mov Disord. 2006;21:1899\u2013907.","journal-title":"Mov Disord."},{"key":"600_CR234","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","volume":"28","author":"EK Perry","year":"1995","unstructured":"Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995;28:240\u201358.","journal-title":"Brain Cogn."},{"key":"600_CR235","doi-asserted-by":"crossref","unstructured":"Bosboom JL, Stoffers D, Wolters E. The role of acetylcholine and dopamine in dementia and psychosis in Parkinson\u2019s disease. J\u00a0Neural\u00a0Transm Suppl. 2003;65:185\u201395.","DOI":"10.1007\/978-3-7091-0643-3_11"},{"key":"600_CR236","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00002093-199307020-00002","volume":"7","author":"EK Perry","year":"1993","unstructured":"Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson\u2019s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69\u201379.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"600_CR237","first-page":"378032","volume":"2015","author":"V Fioravanti","year":"2015","unstructured":"Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P, et al. MRI correlates of Parkinson\u2019s disease progression: a voxel based morphometry study. Parkinsons Dis. 2015;2015:378032.","journal-title":"Parkinsons Dis."},{"key":"600_CR238","first-page":"265","volume":"42","author":"P Riederer","year":"1992","unstructured":"Riederer P, Lange KW, Kornhuber J, Danielczyk W. Glutamatergic-dopaminergic\u00a0balance\u00a0in the\u00a0brain. Its\u00a0importance\u00a0in\u00a0motor disorders\u00a0and\u00a0schizophrenia. Arzneimittelforschung. 1992;42:265\u20138.","journal-title":"Arzneimittelforschung."},{"key":"600_CR239","first-page":"227","volume":"67","author":"M Rodr\u00edguez-Violante","year":"2015","unstructured":"Rodr\u00edguez-Violante M, Cervantes-Arriaga A, Gonz\u00e1lez-Latap\u00ed P, Le\u00f3n-Ortiz P, de la Fuente-Sandoval C, Corona T. Proton magnetic resonance spectroscopy\u00a0changes\u00a0in\u00a0Parkinson\u2019s disease\u00a0with and without\u00a0psychosis. Rev Invest Clin. 2015;67:227\u201334.","journal-title":"Rev Invest Clin."},{"key":"600_CR240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coph.2014.11.001","volume":"20","author":"M Amalric","year":"2015","unstructured":"Amalric M. Targeting\u00a0metabotropic glutamate receptors\u00a0(mGluRs) in\u00a0Parkinson\u2019s disease. Curr Opin Pharmacol. 2015;20:29\u201334.","journal-title":"Curr Opin Pharmacol."},{"key":"600_CR241","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0028-3932(02)00182-3","volume":"41","author":"J Barnes","year":"2003","unstructured":"Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson\u2019s disease. Neuropsychologia. 2003;41:565\u201374.","journal-title":"Neuropsychologia."},{"key":"600_CR242","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/mds.23896","volume":"26","author":"JM Shine","year":"2011","unstructured":"Shine JM, Halliday GM, Naismith SL, Lewis SJ. Visual misperceptions and hallucinations in Parkinson\u2019s disease: dysfunction of attentional control networks? Mov Disord. 2011;26:2154\u20139.","journal-title":"Mov Disord."},{"key":"600_CR243","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"GT Stebbins","year":"2004","unstructured":"Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409\u201316.","journal-title":"Neurology."},{"key":"600_CR244","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","volume":"132","author":"AM Meppelink","year":"2009","unstructured":"Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson\u2019s disease patients with visual hallucinations. Brain. 2009;132:2980\u201393.","journal-title":"Brain."},{"key":"600_CR245","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awr225","volume":"134","author":"DA Gallagher","year":"2011","unstructured":"Gallagher DA, Parkkinen L, O\u2019Sullivan SS, Spratt A, Shah A, Davey CC, et al. Testing an aetiological model of visual hallucinations in Parkinson\u2019s disease. Brain. 2011;134:3299\u2013309.","journal-title":"Brain."},{"key":"600_CR246","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/0891988715598237","volume":"29","author":"S Straughan","year":"2016","unstructured":"Straughan S, Collerton D, Bruce V. Visual priming and visual hallucinations in Parkinson\u2019s disease. Evidence for normal top-down processes. J Geriatr Psychiatry Neurol. 2016;29:25\u201330.","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"600_CR247","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","volume":"27","author":"JH Friedman","year":"2013","unstructured":"Friedman JH. Parkinson\u00a0disease\u00a0psychosis: update. Behav Neurol. 2013;27:469\u201377.","journal-title":"Behav Neurol."},{"key":"600_CR248","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","volume":"12","author":"JG Goldman","year":"2011","unstructured":"Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson\u2019s disease psychosis. Expert Opin Pharmacother. 2011;12:2009\u201324.","journal-title":"Expert Opin Pharmacother."},{"key":"600_CR249","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","volume":"56","author":"CW Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines. Neurology. 2001;56:S1\u201388.","journal-title":"Neurology."},{"key":"600_CR250","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/jnnp.2008.153163","volume":"79","author":"TR Thomsen","year":"2008","unstructured":"Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008;79:1413\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR251","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mds.1258","volume":"17","author":"SA Factor","year":"2002","unstructured":"Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson\u2019s disease. Mov Disord. 2002;17:221\u20132.","journal-title":"Mov Disord."},{"key":"600_CR252","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","volume":"344","author":"B Ford","year":"1994","unstructured":"Ford B, Lynch T, Greene P. Risperidone in Parkinson\u2019s disease. Lancet. 1994;344:681.","journal-title":"Lancet."},{"key":"600_CR253","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","volume":"17","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031\u20135.","journal-title":"Mov Disord."},{"key":"600_CR254","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry. 2002;52:438\u201345.","journal-title":"Biol Psychiatry."},{"key":"600_CR255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","volume":"109","author":"J Schindehutte","year":"2007","unstructured":"Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson\u2019s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109:188\u201391.","journal-title":"Clin Neurol Neurosurg."},{"key":"600_CR256","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","volume":"35","author":"L Pintor","year":"2012","unstructured":"Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35:61\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR257","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","volume":"24","author":"JH Friedman","year":"2011","unstructured":"Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson\u2019s disease. J Pharm Pract. 2011;24:534\u201340.","journal-title":"J Pharm Pract."},{"key":"600_CR258","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","volume":"21","author":"JH Friedman","year":"2006","unstructured":"Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease. Mov Disord. 2006;21:2078\u201381.","journal-title":"Mov Disord."},{"key":"600_CR259","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","volume":"27","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR260","unstructured":"FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioural disturbances. Available at: http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm053171 . Accessed 11 April 2005."},{"key":"600_CR261","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pds.1334","volume":"16","author":"G Trifiro","year":"2007","unstructured":"Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf. 2007;16:538\u201344.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"600_CR262","doi-asserted-by":"crossref","first-page":"e001568","DOI":"10.1161\/JAHA.114.001568","volume":"4","author":"CS Wu","year":"2015","unstructured":"Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015;4:e001568.","journal-title":"J Am Heart Assoc."},{"key":"600_CR263","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","volume":"3","author":"I McKeith","year":"2004","unstructured":"McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19\u201328.","journal-title":"Lancet Neurol."},{"key":"600_CR264","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jamda.2014.11.002","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16:898.","journal-title":"J Am Med Dir Assoc."},{"key":"600_CR265","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","volume":"75","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75:1270\u20136.","journal-title":"Neurology."},{"key":"600_CR266","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson\u2019s disease: positive impact on long-term worsening. Mov Disord. 2008;23:1541\u20135.","journal-title":"Mov Disord."},{"key":"600_CR267","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341.","journal-title":"Lancet."},{"key":"600_CR268","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","DOI":"10.1056\/NEJM199903113401003"},{"key":"600_CR269","doi-asserted-by":"crossref","unstructured":"The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet. 1999;353:2041\u20132.","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"600_CR270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","volume":"17","author":"H Frieling","year":"2007","unstructured":"Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson\u2019s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165\u201371.","journal-title":"Eur Neuropsychopharmacol."},{"key":"600_CR271","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26:S42\u201380.","journal-title":"Mov Disord."},{"key":"600_CR272","first-page":"161","volume":"25","author":"S Kapur","year":"2000","unstructured":"Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161\u20136.","journal-title":"J Psychiatry Neurosci."},{"key":"600_CR273","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","volume":"31","author":"RM Kessler","year":"2006","unstructured":"Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology. 2006;31:1991\u20132001.","journal-title":"Neuropsychopharmacology."},{"key":"600_CR274","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.v59n0101","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59:3\u20137.","journal-title":"J Clin Psychiatry."},{"key":"600_CR275","doi-asserted-by":"crossref","first-page":"e91545","DOI":"10.1371\/journal.pone.0091545","volume":"9","author":"N Hack","year":"2014","unstructured":"Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, et al. An eight-year clinic experience with clozapine use in a Parkinson\u2019s disease clinic setting. PLoS One. 2014;9:e91545.","journal-title":"PLoS One."},{"key":"600_CR276","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e3181c47168","volume":"33","author":"AA Thomas","year":"2010","unstructured":"Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010;33:14\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR277","first-page":"4","volume":"57","author":"E Richelson","year":"1996","unstructured":"Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry. 1996;57:4\u201311.","journal-title":"J Clin Psychiatry."},{"key":"600_CR278","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","volume":"5","author":"P Shotbolt","year":"2009","unstructured":"Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2009;5:327\u201332.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"600_CR279","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","volume":"119","author":"HH Fernandez","year":"2009","unstructured":"Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196\u2013205.","journal-title":"Int J Neurosci."},{"key":"600_CR280","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","volume":"22","author":"JM Rabey","year":"2007","unstructured":"Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration. Mov Disord. 2007;22:313\u20138.","journal-title":"Mov Disord."},{"key":"600_CR281","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"L Morgante","year":"2004","unstructured":"Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR282","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","volume":"29","author":"D Merims","year":"2006","unstructured":"Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol. 2006;29:331\u20137.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR283","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.24942","volume":"27","author":"JH Friedman","year":"2012","unstructured":"Friedman JH. Melperone is ineffective in treating Parkinson\u2019s disease psychosis. Mov Disord. 2012;27:803\u20134.","journal-title":"Mov Disord."},{"key":"600_CR284","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389\u2013409.","journal-title":"CNS Drugs."},{"key":"600_CR285","first-page":"268","volume":"299","author":"DM Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299:268\u201376.","journal-title":"J Pharmacol Exp Ther."},{"key":"600_CR286","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2019-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317:910\u20138.","journal-title":"J Pharmacol Exp Ther."},{"key":"600_CR287","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology. 2010;35:881\u201392.","journal-title":"Neuropsychopharmacology."},{"key":"600_CR288","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340.","journal-title":"Lancet."},{"key":"600_CR289","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JAD-150818","volume":"50","author":"I Yasue","year":"2016","unstructured":"Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson\u2019s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis. 2016;50:733\u201340.","journal-title":"J Alzheimers Dis."},{"key":"600_CR290","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00228-013-1498-4","volume":"69","author":"M George","year":"2013","unstructured":"George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA. Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013;69:1497\u2013509.","journal-title":"Eur J Clin Pharmacol."},{"key":"600_CR291","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci. 2002;23:41\u20133.","journal-title":"Neurol Sci."},{"key":"600_CR292","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988703256054","volume":"16","author":"A Kurita","year":"2003","unstructured":"Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2003;16:184\u20138.","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"600_CR293","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","volume":"25","author":"J Bergman","year":"2002","unstructured":"Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease. Clin Neuropharmacol. 2002;25:107\u201310.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR294","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF03074779","volume":"37","author":"JM Rovers","year":"2006","unstructured":"Rovers JM, Dautzenberg PL, ter Bruggen JP. Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease. Tijdschr Gerontol Geriatr. 2006;37:117\u201320.","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"600_CR295","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R Bullock","year":"2002","unstructured":"Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series. Curr Med Res Opin. 2002;18:258\u201364.","journal-title":"Curr Med Res Opin."},{"key":"600_CR296","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","volume":"76","author":"B Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"600_CR297","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937\u201341.","journal-title":"Int J Geriatr Psychiatry."},{"key":"600_CR298","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","volume":"27","author":"B Dubois","year":"2012","unstructured":"Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230\u20138.","journal-title":"Mov Disord."},{"key":"600_CR299","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171\u20134.","journal-title":"Mov Disord."},{"key":"600_CR300","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/0140-6736(91)91888-2","volume":"338","author":"P Riederer","year":"1991","unstructured":"Riederer P, Lange KW, Kornhuber J, Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson\u2019s disease. Lancet. 1991;338:1022\u20133.","journal-title":"Lancet."},{"key":"600_CR301","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JAD-2005-8307","volume":"8","author":"M Menendez-Gonzalez","year":"2005","unstructured":"Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis. 2005;8:289\u201391.","journal-title":"J Alzheimers Dis."},{"key":"600_CR302","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/gps.1764","volume":"22","author":"V Voon","year":"2007","unstructured":"Voon V, Fox S, Butler TR, Lang AE. Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry. 2007;22:601\u20134.","journal-title":"Int J Geriatr Psychiatry."},{"key":"600_CR303","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1479-8301.2012.00432.x","volume":"13","author":"K Tagai","year":"2013","unstructured":"Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson\u2019s disease: a case report. Psychogeriatrics. 2013;13:103\u20137.","journal-title":"Psychogeriatrics."},{"key":"600_CR304","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0034-1367014","volume":"47","author":"JA Godschalx-Dekker","year":"2014","unstructured":"Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry. 2014;47:81\u20133.","journal-title":"Pharmacopsychiatry."},{"key":"600_CR305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2006.06.016","volume":"31","author":"G Meco","year":"2007","unstructured":"Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:311\u20133.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"600_CR306","first-page":"1750","volume":"150","author":"EC Lauterbach","year":"1993","unstructured":"Lauterbach EC. Dopaminergic hallucinosis with fluoxetine in Parkinson\u2019s disease. Am J Psychiatry. 1993;150:1750.","journal-title":"Am J Psychiatry."},{"key":"600_CR307","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2007-979504","volume":"30","author":"C Normann","year":"1997","unstructured":"Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry. 1997;30:263\u20135.","journal-title":"Pharmacopsychiatry."},{"key":"600_CR308","first-page":"1629","volume":"10","author":"CH Yu","year":"2014","unstructured":"Yu CH, Ishii R, Yu SC, Takeda M. Yokukansan and its ingredients as possible treatment options for schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1629\u201334.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"600_CR309","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hup.2286","volume":"28","author":"Y Matsuda","year":"2013","unstructured":"Matsuda Y, Kishi T, Shibayama H, Iwata N. Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2013;28:80\u20136.","journal-title":"Hum Psychopharmacol."},{"key":"600_CR310","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-013-1105-y","volume":"121","author":"T Hatano","year":"2014","unstructured":"Hatano T, Hattori N, Kawanabe T, Terayama Y, Suzuki N, Iwasaki Y, et al. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson\u2019s disease. J Neural Transm. 2014;121:275\u201381.","journal-title":"J Neural Transm."},{"key":"600_CR311","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0000000000000122","volume":"39","author":"K Abe","year":"2016","unstructured":"Abe K, Chiba Y, Katsuse O, Hirayasu Y. A case of Parkinson disease with both visual hallucination and pain improved by gabapentin. Clin Neuropharmacol. 2016;39:55\u20136.","journal-title":"Clin Neuropharmacol."},{"key":"600_CR312","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0b013e3181c18a3d","volume":"26","author":"S Ueda","year":"2010","unstructured":"Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT. 2010;26:111\u20135.","journal-title":"J ECT."},{"key":"600_CR313","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00702-014-1212-4","volume":"121","author":"K Nishioka","year":"2014","unstructured":"Nishioka K, Tanaka R, Shimura H, Hirano K, Hatano T, Miyakawa K, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson\u2019s disease with refractory psychiatric symptoms. J Neural Transm. 2014;121:1405\u201310.","journal-title":"J Neural Transm."},{"key":"600_CR314","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1176\/jnp.15.4.407","volume":"15","author":"R Kennedy","year":"2003","unstructured":"Kennedy R, Mittal D, O\u2019Jile J. Electroconvulsive therapy in movement disorders: an update. J Neuropsychiatry Clin Neurosci. 2003;15:407\u201321.","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"600_CR315","doi-asserted-by":"crossref","unstructured":"Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, et al. Improvements in both psychosis and motor signs in Parkinson\u2019s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1704\u20138.","DOI":"10.1016\/j.pnpbp.2011.05.003"}],"updated-by":[{"DOI":"10.1007\/s40265-016-0624-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0600-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0600-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:55:21Z","timestamp":1748973321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0600-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":315,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0600-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]}}}